ArticleCureus2026
Rethinking Goods and Services Tax (GST) and Academic Research in India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Goods and Services Tax (GST), introduced in India on July 1, 2017, was envisioned as a landmark reform to unify indirect taxation, enhance transparency, and reinforce fiscal federalism. While celebrated for its efficiency, its uniform application to research‑related activities has generated significant concern across academia, medicine, and public health. Conference registration fees and continuing medical education (CME) costs have risen sharply, restricting opportunities for skill development among doctoral students, postdoctoral fellows, clinicians, and public health professionals. Escalating publication charges and subscription cancellations in state universities, teaching hospitals, and research institutes have curtailed access to international medical literature, limiting evidence‑based practice, policy formulation, and equitable knowledge dissemination. Procurement delays in national laboratories and medical research centers further impede innovation, slowing translation of discoveries into improved diagnostics, therapeutics, and preventive strategies. From the government's perspective, uniform taxation prevents loopholes, curbs misuse of exemptions, and ensures consistency in revenue collection, with GST revenues earmarked for infrastructure, healthcare, and education. Yet, the imposition of an 18% GST on research and CME activities clashes with the lived experiences of researchers and healthcare professionals, who view it as undermining accessibility, equity, and timely adoption of global best practices. The downstream effects include weakened epidemic preparedness, delayed integration of innovations into healthcare delivery, and widening disparities in public health outcomes. Formal petitions from scientific academies, medical associations, industry bodies, and state assemblies underscore the urgency of reform. International comparisons reveal alternative fiscal models that balance efficiency with recognition of research and CME as public goods. This editorial argues for targeted reforms, such as concessional rates, exemptions for academic medical services, and sector‑specific subsidies, to align fiscal policy with India's innovation and public health goals, ensuring taxation does not become a barrier to advancing healthcare equity and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.